Why the study?
Although ACEIs and ARBs are known to counteract the role of Ang II in initiating inflammation, details explaining how they reduce inflammation warranted review.
Do ACE inhibitors and ARBs reduce inflammation?
Do ACE inhibitors and ARBs reduce inflammation?
This review highlights that ACE inhibitors and ARBs provide cardioprotective and nephroprotective benefits by modulating inflammatory pathways.
Answers are grounded in this paper and cite their sources.
Supports ACEI/ARB use in CV and renal disease; confirms anti-inflammatory mechanisms in Level 1 evidence.
The renin-angiotensin system (RAS) was thought to be in charge of managing blood pressure and electrolytes. It has been established that angiotensin II is also responsible for controlling inflammation in addition to blood pressure and potassium levels. Angiotensin converting enzyme 2 (ACE2), angiotensins (1–7), angiotensins (1–9), and other additional RAS components have been identified, and have anti-angiotensin II effects. Both angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) are utilized as anti-hypertensive medications and protecting the heart and kidneys, and counteract the part played by Ang II in the initiation of inflammation. This review provides crucial details that help explain how ACEI and ARBs reduce inflammation. Using reliable websites like Google Scholar, PubMed, and ResearchGate, the most recent publications were reviewed. Search terms have included "RAS role of Ang II in inflammation," "influence of ACEI," and "effect of ARBs on PPAR-gamma." The data were gathered from controlled clinical trials, in vitro studies, and animal-based studies; preprints, article reviews, and meta-analysis studies were excluded. Both ACEIs and ARBs reduce inflammation via a variety of mechanisms, which explains their cardioprotective and nephroprotective effects. They reduce inflammation by modulating an inflammatory pathway through either similar or dissimilar mechanisms.
No takes yet. Share an insight, caveat, or question.
Hamaamin et al. (2022) conducted a review in Inflammation. ACE inhibitors and Angiotensin Receptor Blockers (ARBs) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: